Genmab — Oktober 2025
-
Petosemtamab shows first colorectal promise https://www.oncologypipeline.com/apexonco/petosemtamab-shows-first-colorectal-promise
-
teclistamab - Myeloma Drug Performs Well in Autoimmune Diseases https://www.medpagetoday.com/rheumatology/generalrheumatology/117966
-
TECVAYLI
plus DARZALEX FASPRO combination regimen significantly
improves progression-free survival and overall survival versus standard of care https://www.jnj.com/media-center/press-releases/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free-survival-and-overall-survival-versus-standard-of-care -
- At almost three years follow-up, the combination of TECVAYLI and DARZALEX FASPRO met the primary endpoint of progression-free survival (PFS) - Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results
-
J&J claims a Tecvayli/Darzalex combo win https://www.oncologypipeline.com/apexonco/jj-claims-tecvaylidarzalex-combo-win
-
Genmab-partner viser bedre overlevelsesmuligheder for kræftsyge i kombinationsstudie https://proinvestor.com/investornyt/1371488/genmab-partner-viser-bedre-overlevelsesmuligheder-for-kraeftsyge-i-kombinationsstudie
-
Her en vurdering med hjælp fra copilot med info fra Proinvestor. Hvis Tecvayli/Darzalex bliver en ny SOC i relapsede/refraktære myelom-patienter, kan royalty-strømmen blive en vigtig vækstdriver for Genmab – især hvis Darzalex fortsætter sin blockbuster-status og Tecvayli bliver en fast del af regimet.
-
Vel bare ligeså ustabil som resten af markedet p.t
-
Aktier: Er det korrektionstid? https://proinvestor.com/boards/128988
-
earlier Interview Jan van de Winkel: keynote speaker of the 2025 Utrecht Science Lecture. https://www.utrechtsciencepark.nl/en/about/view/stories-interviews/interview-jan-van-de-winkel-keynote-opening-utrecht-science-week-september-26
-
One of the first ESMO sessions , Rinatabart mentioned https://x.com/omalirp/status/1979131841329197409/photo/1
-
Uagtet at det er et lille studie, så ser dataene meget lovende ud. Responsraten på 50% er høj for patienter, der har mislykkedes med standardbehandlinger – det er bedre end mange eksisterende muligheder. Den varige effekt (63% fortsatte respons efter 1 års opfølgning) tyder på, at behandlingen holder længe.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind